Polymeric
Engineering and Controlled Release Mechanisms in Transdermal Antihypertensive
Systems: Scientific Progress and Industrial Implications
Syed Imran1*, Dr. Prafulla Prakash Adkar Patil2
1 Research Scholar,
Sunrise University, Alwar, Rajasthan, India
syedimran665@gmail.com
2 Professor, Department of
Pharmaceutical Sciences, Sunrise University, Alwar, Rajasthan, India
Abstract: Hypertension is still one of the most serious global health problems and requires continuous management with medications used over long periods of time. Successful management of hypertension involves maintaining constant and consistent plasma levels of medication in order to achieve therapeutic effectiveness. The traditional methods of delivering medications via the oral route have not provided a mechanism for long-term, sustained and controlled release of medications throughout the duration of therapy. This can lead to inconsistent plasma concentrations of drugs and a lack of compliance by patients to their medication regimen. In light of this finding, transdermal drug delivery systems made of polymers present a new way to deliver antihypertensive medications due in part to their ability to control the rate of drug release from the device providing better therapeutic results.
This research will provide an analysis of the polymer engineering and controlled-release mechanisms involved in designing transdermal drug delivery systems for the delivery of antihypertensive drugs using an analytical approach that utilizes secondary data from the literature. The data collected for this research project will be obtained from published journal articles, pharmaceutical product databases and material science literature as well as examining new products involving polymeric drug delivery. The analysis will focus on four areas; 1) polymer types and matrix design, 2) controlled-release mechanisms used for the release of drugs including diffusion, swelling and erosion, and 3) new technologies including smart polymers and nanocomposites, 4) industrial and clinical implications associated with the manufacturing scalability, import/export regulations and regulatory issues related to these new products.
Research reveals that drug stability, permeability, and controlled release, and thus therapeutic consistency of drugs are greatly improved by polymer engineering. Advanced polymers and systems, particularly stimul-responsive and hybrid systems, also show much promise as viable means of improving the transdermal delivery of drugs. Nonetheless, the issues of pricing, reliability, and regulatory standardization continue to exist.
The findings suggest that integrating polymeric materials into pharmacokinetics will yield a strong basis for developing effective transdermal antihypertensive delivery systems. Thus, ongoing advancement and cooperative interdisciplinary efforts will propel this field into the future.
Keywords: Polymer engineering, Controlled release, Transdermal drug delivery, Antihypertensive therapy, Drug delivery systems
1.
INTRODUCTION
High blood pressure or Hypertension
is a chronic disease, which is therefore non-communicable and cannot be
transmitted between individuals, that increases your risk for cardiovascular
disease (e.g., heart attack and stroke). Hypertension is now one of the leading
causes of death in the world, and affects more than one billion people and is
contributing to the world's burden of disease. A key driver of the global
growing prevalence of hypertension is changes to diet, an increased urban
population, an ever-increasing population with a life expectancy of over 65
years, and sedentary lifestyles. All of these factors combine to make
hypertension a serious and growing public health concern that needs long-term
treatment (Whelton et al., 2018).
Sustained pharmacological therapy is
necessary for the management of hypertension to maintain normal blood pressure
levels. Traditional forms (like oral tablets or capsules) do not allow for
stable levels of medicine in the body because of such factors as: first-pass
metabolism, variable gastrointestinal absorption and need for frequent dosing
create fluctuations of the drug concentration. These fluctuations can result in
both reduced therapeutic activity and increased adverse effects. Long-term
treatment regimens, often lead to low patient compliance and high rates of
non-compliance in managing their illness.
With the increasing need for new
technologies to deliver antihypertensive medications by way of controlled
dosage and extended duration, the desire to provide long term pharmaceutical
activity—or 'sustained release'—is significant. In other words, a controlled
drug delivery system aims to keep drug levels in the therapeutic range or
'window' for longer; thus, improving effectiveness and minimizing side effects.
Due to the potential of controlling the rate of drug delivery, polymer based
drug delivery systems (PDDs) have been developed due to the variety of
approaches that can be taken to manipulate the physical and chemical
characteristics of polymeric materials.
Historically, the evolution of PDD
technology has changed how pharmaceutical dosage forms are manufactured. For
instance, PDD technology initially used simple polymer matrices that contained
drug molecules to provide a controlled release profile. As the development of
polymeric materials became more sophisticated, so did the way we used polymers
in the manufacture of pharmaceutical dosage forms, becoming more capable of
creating complex polymeric systems that could provide specific control over
drug delivery. Through careful manipulation of the physicochemical properties
of polymers (such as molecular weight, solubility, and cross-linking density),
a variety of release profiles can now be achieved with polymeric systems.
Because of this progression, polymeric systems are now valuable components of
modern drug delivery systems, particularly in transdermal systems, where
controlled and sustained release is critical (Langer & Peppas, 2003).
The use of polymers is essential for
developing and designing transdermal drug delivery systems, which are made to
function properly. In pharmaceuticals, they are classified as massive molecules
made up of repeating units of a unique structure, which makes them versatile
enough to be made so they have specific characteristics related to their
physical, chemical, and mechanical properties. Polymers are the base material
of transdermal patches and have an impact on the following attributes: drug
release; mechanical strength; how well it sticks to the skin; and overall
system stability.
The primary function of polymers in
transdermal systems is to provide a matrix or reservoir in which the drug is
contained. The polymer matrix or reservoir will dictate the time it takes for
the drug to be released from its storage container and for it to disperse
through the skin; therefore, polymers allow for controlled release of
medications over a long period. Also, the adhesive properties of the patch will
be dictated by the type of polymer that was used to manufacture it. The patch’s
level of comfort and wear will also vary based on the polymer type. These
properties affect the design of a transdermal patch and thus need to be
considered together when designing a patch (Park et al., 2014).
Transdermal systems utilize
different types of polymers classified by their origin: natural or synthetic.
Natural polymers, like chitosan, gelatin, and cellulose derivatives, are
obtained from natural sources and exhibit good biocompatibility and
biodegradability. By contrast, synthetic polymers, such as polyvinyl alcohol
(PVA), polyethylene glycol (PEG), and ethylene-vinyl acetate (EVA), provide
more control of physical and chemical characteristics and are commonly used in
commercial products.
Choosing the correct polymer
involves many factors, including compatibility with the drug formulation, the
necessary drug release rate from the patch, and how much strength is required
by the patch.
Despite advances in transdermal
delivery systems, numerous problems still exist today with treating high blood
pressure using polymer-based transdermal patches. The most significant problem
is that traditional transdermal patches have variable rates of drug delivery
due to variation in polymer type, arrangement of the drug within the polymer,
and conditions the patch is in at the time of use. These factors affect the
drug-supply rate and ultimately determine how effective the drug will be.
Another serious issue with polymer
transdermal patch formulations is polymer stability and degradation. Polymers
can degrade due to physical changes to the polymer structure or chemical
changes to the polymer, or through interaction with the drug or the
environment. These types of conditions will lead to diminished transdermal
patch performance, problems with releasing the drug at the right rate, and loss
of patch mechanical strength. Each of these variables will greatly affect how
long the transdermal system will last and how dependable it will be.
Many available topical drugs do not
provide optimized release kinetics, and although pharmaceutical scientists have
made significant strides to optimize the onset and duration of drug delivery
and maintain stable plasma levels, the challenge of developing rapid and
sustained delivery of antihypertensive medications remains complex. In order to
overcome these limitations, there is an urgent need for advanced engineering of
polymers to address these issues and improve the effectiveness of topical
delivery systems.
Increased interest in pharmaceutical
delivery systems with controlled release has led to significant investment in
polymer-based topical delivery systems. Because hypertension requires
long-acting/consistent administration of medication, the development of
delivery systems that maintain relatively constant levels of drug are critical.
Not only do controlled release systems provide a better outcome therapeutic
solution, but they also allow patients to take their medications more
regularly.
In addition to improving the
consistency of therapeutic outcomes through controlled release, fluctuations in
drug concentrations can result in a period of inadequate therapy or a period of
increased risk of developing side effects. The development of polymeric
delivery systems for controlled drug delivery offers the potential to eliminate
inconsistencies and provide precisely controlled release of drugs.
Polymeric innovations are essential
to develop next-generation drug delivery systems from an industrial standpoint Pharmaceutical
companies are looking to utilize advanced materials to enhance the stability of
drugs, increase drug delivery efficiency, and meet regulatory requirements. In
light of the need to build on advances made in polymer science in order to
improve the ability of polymer manufacturers to produce commercially viable
polymer products, it is important for researchers involved in polymer science
to have an understanding of the progress that has been made in polymer
engineering from both a scientific and commercial perspective.
This research will focus on the
investigation of developments in polymer engineering and the control of drug
release in transdermal systems for the delivery of antihypertensives via the
use of material science combined with pharmaceutical formulation research,
which will ultimately help to develop improved designs and functionality of
transdermal drug delivery systems.
The research will include a detailed
analysis of the design and functionality of polymer matrices that are used to
develop transdermal drug delivery systems, the various mechanisms by which
drugs are released from transdermal drug delivery systems including methods for
controlling the release rate, and an assessment of the effectiveness of using
intelligent or responsive polymers to increase the therapeutic efficacy of
antihypertensives delivered via a transdermal route.
Additionally, this research will
assess the potential for transdermal drug delivery systems based on polymer
materials to be manufactured at an industrial scale and the regulatory
significance of those products as a novel pharmaceutical material for the
production of contemporary drugs.
In this study, I primarily undertook
an analytical review of previously published literature, which involved
obtaining information from various reputable sources (both paid and free) such
as PubMed, Science Direct (open access), World Health Organization and Google
Scholar. Search strategies were utilised to identify studies that met the
pre-determined inclusion criteria for the research studies associated with
polymer-based systems designed for use in transdermal drug delivery or
controlled drug release systems.
The published literature, databases,
scientific journal articles and peer reviewed journals were systematically
searched to provide insight into advancements made in the area; identify
trends; and establish research gaps therein. The results of the analysis were
categorised by the three main topics: design characteristics of polymer matrix
systems; mechanisms of drug release; and advanced technologies of polymer
systems. An evaluation of the effects and sustainability of polymer based drug
delivery systems was conducted using the findings based on analysis of their
current status in conjunction with antihypertensive treatments. The methodology
utilised in this study provided a systematic and comprehensive analysis of what
is currently known and thus provides justification for any conclusions or
recommendations made.
2. POLYMERIC
MATERIALS AND MATRIX DESIGN IN TDDS
The fundamental component of
Transdermal Drug Delivery Systems (TDDS) is polymeric materials that are
responsible for building the structural and functional framework that dictates
how drugs leave the patches, how well the patches are structurally stable, and
also how acceptable the patches will be to the patients who use them. Proper
selection of polymers and optimization of the matrix architecture can have a
significant effect on the design of an effective transdermal patch as well as
providing for the proper rate of drug delivery and sufficient mechanical
stability of the patch. The advancements in polymer science have provided for
the development of innovative TDDS that can consistently deliver
antihypertension medications in an efficient manner.
Types of Polymers Used
TDDS (transdermal drug delivery
systems) use two types of polymers: natural and synthetic. Natural polymers
such as chitosan and gelatin have advantages such as biocompatibility,
biocompatible properties, biodegradability, low toxicity, etc. Chitosan is a
polysaccharide based on chitin's polysaccharide structure. It is an excellent
film forming material and has bioadhesive properties, making it very suitable
for application as a transdermal drug delivery system. Similarly, gelatin is a
workable and flexible filmforming protein polymer and can encapsulate various
drugs. However, natural polymers are subject to variability in their properties
and lack significant mechanical strength, which can limit their application in
long-term applications. On the other hand, synthetic polymers allow the user to
make better control of the physical and chemical properties and, therefore,
more synthetic polymers are used commercially for transdermal product lines
compared to natural polymers. The ethylene-vinyl acetate (EVA) polymer is one
of the most commonly used synthetic polymers due to its stability, flexibility
and ability to regulate drug diffusion across the skin. Hydroxypropyl
methylcellulose (HPMC) is an important synthetic polymer used to make films
that can be flexible and will provide controlled drug release from the film
that is created. Polyvinyl alcohol (PVA) is another commonly used polymer for
transdermal drug delivery systems due to its hydrophilic nature and its ability
to be compatible with many different types of drugs. Both of these polymers can
be adjusted and engineered to achieve appropriate mechanical properties and
release profiles, making them viable options for antihypertensive drug delivery
systems (Kwon & Kim, 2017).
Polymer Matrix Architecture
A key element in the transdermal
patch performance is the structure of the polymer matrix itself. In fact, there
are three types of systems that may be present in a transdermal patch:
reservoir systems, matrix systems and adhesive systems. In the reservoir type
patch, you have a compartment containing drug (the reservoir) that is
surrounded by a polymer membrane in order to regulate the rate of drug
delivery. The design allows for precise control of drug delivery, but if the
membrane were to rupture, it could create a risk of dose dumping.
Matrix systems are more commonly
used because they are simpler and more reliable than reservoir systems. The
drug is dispersed uniformly in the polymer matrix, and diffusion is used for
drug release. Matrix systems are generally more stable than reservoir systems
and have less chance of failure than reservoir systems. The adhesive system
incorporates the drug directly into the adhesive layer of the patch, thereby
making construction simpler and providing for greater comfort to the patient.
Adhesive systems will typically provide greater contact between the patch and
the patient's skin which is critical to the effective absorption of the drug (Guy,
2010).
Polymer–Drug Interactions
Transdermal delivery systems'
effectiveness and stability are greatly influenced by how well drugs interact
with the polymers used to make them. First, the drug must be compatible with
the polymer, so that the drug distributes evenly throughout the polymer matrix
for proper drug loading. Otherwise, when these two substances aren't
compatible, the drug could crystallize, separate into phases, or have decreased
bioavailability.
In general, the stability of the
drug-polymers interactions can impact both the chemical and physical
stabilities of the system as a whole. The properties of the polymer, such as
its composition, molecular weight, and cross-linking density can all play a
role in determining how fast or slow the drug will be released from the
transdermal delivery system and its overall shelf life. Therefore, it is
important to optimize how these interactions occur to ensure continued
consistency in providing therapeutic effects to customers across the entire
shelf life of the product, as well as preventing degradation during storage
(Siepmann & Siepmann, 2012).
Influence on Mechanical and Adhesive
Properties
Polymers govern both the adhesive
and mechanical performance of transdermal patches. The flexibility of the
polymer alone will allow the patch to remain intact and functionable, enabling
the wearer to perform normal daily functions without jeopardizing the patch’s
structural integrity. Additionally, having the polymer exhibit sufficient
elasticity and tensile strength contributes to the adequate durability of the
overall system.
Skin adhesion is also an important
factor in ensuring proper drug delivery through the patch. In order for a drug
delivery system to be effective, the patch must continuously deliver drugs by
being in direct contact with the outer layer of the skin. The adhesive layer
must therefore consist of a polymer that provides both an adequate amount of adhesion
and will not cause irritation or discomfort to the wearer. The bioadhesive
properties of the patch will help keep it in position on the skin, allowing the
wearer to absorb as much drug as possible during the desired period of time.
Furthermore, the patch should be easily removable from the skin without leaving
any residue and without causing any damage to the skin itself. The balance
between providing appropriate levels of adhesion to the skin and preventing
irritation or discomfort will enhance adherence/compliance of the patient and
will thus improve the overall success of the therapy (Pastore et al., 2015).
As such, the material and matrix
design of the polymer is key in producing an effective transdermal delivery
system for the antihypertensive medication. The careful selection and design of
the polymer provides for a controlled-release of the drug, mechanical stability
and improved patient experience, which increases the overall efficiency of
transdermal therapy.
3.
CONTROLLED RELEASE MECHANISMS IN POLYMERIC SYSTEMS
Managed release devices are critical
to the effectiveness of transdermal polymer drug delivery methods, especially
for diseases that require constant plasma drug levels (e.g., hypertension).
Controlled release devices control the way drugs are released from their
polymer matrices and how they travel through the skin over time. Control over
drug release rates through the use of polymers aids in keeping drugs at
therapeutic levels, decreasing how often drugs need to be taken, and reducing
adverse reactions. Recent advancements in material engineering and mathematical
design have strengthened the reliability and efficacy of managed release
systems (Siepmann & Peppas, 2011).
Diffusion-Controlled Release
Drug distribution through polymeric
drug delivery systems typically utilizes diffusion-controlled release
mechanisms. According to Fick's law of diffusion, drug distribution through the
transdermal system takes place in a manner that allows diffusion from an area
of greater concentration of drug to an area of lesser concentration of drug. In
order for a drug to be released from a polymeric matrix of a transdermal
delivery system, there must be a diffusional transfer of the drug through both
the polymer matrix and the skin. Factors that affect the rate of diffusion
include the concentration gradient, diffusion coefficient, and polymer matrix
thickness.
When polymer chains are closely spaced
together within the polymer, diffusion is limited and results in a much slow,
steady release of the drug; when the polymer matrix has a high porosity, the
drug diffuses from the polymer matrix more rapidly. Systems that provide
controlled drug release by diffusion have many advantages that make them a
valuable method for delivering drugs; for example, controlled release systems
generate a predictable and repeatable rate of medication release, which is
necessary for effective long-term management of hypertension for people who are
taking anti-hypertensive medications (Crank, 1975).
Swelling-Controlled Systems
Polymers are able to expand by
absorbing biological fluids, which means that they can create systems that are
controlled by swelling. When the hydrophilic region of a polymer comes into
contact with moisture from the skin, that region will hydrate and swell,
thereby forming a gel-like substance. This process of swelling will increase
the amount of available volume within the polymer matrix, and enable drug
molecules to diffuse out of the polymer matrix more easily.
Determining the amount of drug that
will be released from a swelling-controlled system will greatly depend on how
fast and how much the system swells. Initially, there may not be a lot of
hydration to release the drug so the drug will not be released from the polymer
matrix at a fast rate. However, as time passes, the polymer will swell and
cause the drug to be released at a faster rate. The rate of swelling versus the
rate of diffusion ultimately will affect the overall release profile.
Hydroxypropyl methylcellulose and polyvinyl alcohol are the two best-known
polymers when looking at swelling-controlled systems since they both have a
high capacity to absorb water and are biocompatible. Swelling-controlled
systems are especially useful in the development of controlled and extended
release delivery of medications in transdermal delivery systems (Peppas &
Sahlin, 1996).
Erosion-Controlled Mechanisms
Release of an encapsulated drug
trapped inside a polymeric matrix is accomplished through the erosion of the
polymer over time and the erosion of the polymer is responsible for drug
release rather than solely through diffusion. Therefore, this type of release
mechanism is especially advantageous for long-term delivery of drugs since it
promotes a consistent release rate of drugs over an extended period of time.
Erosion of polymers can take place
via a variety of mechanisms including hydrolysis as well as enzymatic
degradation. Erosion-controlled drug delivery devices frequently utilize
biodegradable polymers such as polylactic acid (PLA) or polyglycolic acid (PGA).
When the polymer is eroded, the drug is sequentially released into the local
environment. Such a drug release mechanism is advantageous for transdermal
systems because it minimizes the likelihood of dose dumping and promotes
prolonged therapeutic activity (Siegel & Rathbone, 2012).
Mathematical Modeling of Drug
Release
Mathematical modeling is extremely
important to help predict and understand the release of drugs from polymeric
systems. The Higuchi model is one of the first models created to explain how
drugs are released, and it uses the square root of time based on the principles
of diffusion to indicate when a certain amount of drug will be released from
the matrix. This model works best in a matrix system where the drug is evenly
distributed throughout the polymer.
The Korsmeyer–Peppas model gives a
more generalized way of characterizing different release methods (e.g.,
diffusion, swelling, erosion). This model does this by allowing an exponent to
be added to the equation, indicating what type of release mechanism is being
used. This use of exponents helps investigators gain insight into how these
mechanisms impact drug release.
Both of these models serve as an
important tool for developing transdermal formulations by helping to
characterize how drugs will be released and allowing for modification of the
formulation to provide the desired therapeutic effect. The use of controlled
release systems along with these modeling techniques allows for precisely
controlled drug delivery profiles, providing greater benefits and fewer
negative effects on patients (Costa & Sousa Lobo, 2001).
4. ADVANCED
POLYMER ENGINEERING AND INNOVATIONS
Transdermal Drug Delivery Systems
(TDDS), have been radically improved by advancement in aspects of polymer
engineering, such as, precise control of drug release, drug permeability, and
improved therapeutic performance. This is especially important in the treatment
of hypertension because of the requirement for continuous and predictable drug
delivery; therefore, the advancement of innovative polymers has provided new
and improved methods of delivering antihypertensive medications to patients via
TDDS. Examples of these improvements include, "smart" polymers; nanocomposite
polymer systems; biodegradable polymer systems; and the combination of any/all
of these systems is now allowing patients to receive their antihypertensive
medications using a more efficient TDDS.
Smart and Stimuli-Responsive
Polymers
Stimuli-responsive polymers are a
significant advancement in delivery systems that offer improved control over
medications. Their unique properties allow the materials to change their
physical/chemical characteristics when exposed to specific external or internal
stimuli such as temperature, pH, or ionic strength. For example,
temperature-sensitive polymers have critical temperatures at which they
experience phase changes, which enables the release of a drug in direct
response to the temperature of the human body. The ability to regulate drug
release or diffusion based upon a change in human body temperature is an asset
for transdermal systems where changes in temperature can be used locally to
regulate drug delivery rates.
Another example is pH-responsive
polymers that swell and/or shrink depending upon their environment’s pH. The
skin is fairly stable regarding pH; however, such systems can still be designed
in order to respond to localized or microenvironmental pH changes thereby
providing an additional means of increasing the accuracy of drug delivery.
These smart polymers will provide on demand or on the spot drug delivery and
therefore may enhance therapeutic outcomes by minimizing variability in drug
concentration (Stuart et al., 2010).
Nanocomposite and Hybrid Polymer
Systems
Polymers can be combined with
nanomaterials to create hybrid polymer/nanocomposite systems for transdermal
drug delivery. Nanoparticles, including solid lipid particles, metal particles,
or silica-based particles, can enhance the drug load capacity, increase
permeability, and improve stability of the transdermal drug delivery system by
being incorporated into polymer matrices. In addition to offering structural
support through the polymer matrix and providing controlled release, the
presence of nanoparticles provides additional penetration and provides
protection from drug degradation.
These hybrid systems can also change
the formulation’s physicochemical characteristics to improve their interaction
with the stratum corneum (skin barrier). The increased number of nanoparticles
enhances the total surface area of the product and increases the ability of the
formulation to penetrate into the skin layers. Nanocomposite systems will also
exhibit greater mechanical strength and stability; therefore, they are an
excellent candidate for long-term use in the treatment of hypertension (Kumar
et al., 2016).
Bioadhesive and Biodegradable
Polymers
Bioadhesive polymers can improve the
ability of transdermal patches to stick to a person's skin so that they will
stay on longer, which may result in producing a better therapeutic effect from
medications provided via the patches. Bioadhesive polymers increase adhesion of
a patch to the skin through various bonding mechanisms with the skin, such as
by hydrogen bonds and/or electrostatic interactions; thus, increasing the
length of time that the patch can remain on the skin increases the length of
time that drugs delivered via transdermal patches will penetrate through the
skin. Improved adhesion and therefore longer duration of wear will improve
patient compliance because it will keep the transdermal patch on throughout the
day despite normal patient activities (i.e., removing the patch will cause a
patient to not use the transdermal patch.)
Biodegradable polymers are also
increasing in popularity because of the environmental benefits and clinical
benefits associated with them. They meet the clinical definition of being
biodegradable by degrading into non-toxic byproducts after being used, thereby
minimizing the impact on the environment and eliminating a potential barrier
for patients in need of transdermal patches. Similarly, there are a number of
biodegradable polymers, such as PLA and chitosan, used in transdermal patch
devices that exhibit biocompatibility and are designed to degrade in a
controlled manner. The use of biodegradable materials in the manufacture of
transdermal patches supports the push for sustainability in the pharmaceutical
industry (Nair & Laurencin, 2007).
Polymer Engineering in
Antihypertensive Delivery
Through the use of polymer
engineering, researchers have identified significant opportunities for
improving the transdermal delivery of antihypertensive medications such as
propranolol and clonidine, primarily due to their low oral bioavailability and
the necessity for the maintenance of steady state plasma concentrations over
the duration of treatment. Transdermal polymeric delivery methods, such as
transdermal patches, provide a sustained drug delivery method that allows for a
steady-state drug concentration to be reached and maintained over an extended
period.
Propranolol-containing polymeric
patches have been shown to improve bioavailability; reduce the frequency of
dosing; and control blood pressure over the long term when used in conjunction
with clonidine. The polymers that comprise the patch can be used to modulate the
release rate of the drug from the patch and can facilitate the ongoing release
of the drug through the patch, giving more consistent therapeutic effects and
improving compliance by patients. Polymer engineering offers substantial
advantages for optimizing antihypertensive therapies (Prausnitz & Langer,
2008).
Challenges in Polymer-Based Systems
Polymer technology has achieved
great advancements over the years; however, there is still room for further
improvement when it comes to developing next-gen transdermal delivery systems.
One of the most significant issues associated with the development of
transdermal systems is toxicity. Many of the current polymers used for
transdermal delivery systems (both synthetic and nanocomposites) can
potentially result in skin irritation and/or other negative reactions if they
are not formulated correctly. Therefore, biocompatibility and safety will
continue to be important factors when developing transdermal systems.
Another challenge facing
polymer-based systems is long-term stability and shelf-life. Properties of
polymeric drug delivery systems are susceptible to change (either physically or
chemically) during storage, and these changes may ultimately impact the drug-release
profiles and efficacy of the drug. Environmental factors (e.g.,
temperature/humidity/light) can negatively impact the stability of polymeric
drug delivery systems.
Finally, the costs associated with
high-tech materials and new manufacturing processes will continue to limit the
potential for establishing widespread use of polymeric drug delivery
technologies. Consequently, developing cost-effective and scalable solutions
will be necessary to move from laboratory testing to commercially available
products. Resolving issues associated with the toxicity, shelf-life, and
manufacturing costs will play a critical role in the continued development and
successful commercial introduction of polymeric transdermal drug delivery
systems.
5.
INDUSTRIAL AND CLINICAL IMPLICATIONS
For transdermal antihypertensive systems based on polymers, a successful transition from the laboratory setting into the marketplace is dependent on manufacturing scalability/feasibility. Manufacturing methods for the fabrication of transdermal patches have been developed that include solvent-cast, hot melt extrusion, and laminating. Of these methods, solvent-casting has been the method most commonly associated with the manufacturing of transdermal systems due to its relative simplicity and ability to create uniform films of controlled thickness. Hot melt extrusion also has some advantages, such as the ability to create products without using organic solvents, and has better processing economies and efficiencies in comparison to other methods of manufacture, therefore is more applicable to large scale industrial output.
When defining scalability for transdermal systems, consideration must also be given to the selection of appropriate manufacturing methods. Additionally, scalability will require process parameter optimization that will yield consistent, reproducible and high-quality systems; manufacturers must be concerned about the overall cost of producing transdermal patches, especially when using sophisticated polymers or nanocomposite materials. Although innovative materials may enhance performance, they frequently contribute to increasing production costs, limiting commercial viability. Therefore, in order for transdermal systems to be adopted widely for treating hypertension, a balance between technological advancement and economic feasibility must be found.
There are strict regulations governing the development and commercialization of transdermal delivery systems to maintain product safety, efficiency and quality. Regulatory authorities require an extensive amount of evaluation for each polymer based patch, including preclinical and clinical studies, to evaluate multiple criteria such as drug release rates, skin irritating potential and long-term stability of the finished product. All aspects of quality must be upheld throughout the entire manufacturing process including selecting the materials used, designing the formula and conducting testing on final products. Safety and effectiveness requirements are even more critical for the delivery systems used in antihypertensive therapy as these drugs are intended for use over an extended period of time. Regulatory guidance specifies that there must be consistent drug delivery, minimum adverse events and predictable performance across variances in conditions. In addition to following good manufacturing practices, manufacturers must maintain accurate record of all aspects of their manufacturing processes including validation, documentation and quality control. Establishing criteria for evaluating polymer-based systems continues to be a challenge due to the introduction of new technologies.
Recently, there has been tremendous growth in the transdermal drug delivery system market worldwide. Much of this growth has been due to the rising number of people seeking non-invasive and easy-to-use therapies, plus the increase in incidences of chronic illness, such as hypertension. Because polymeric transdermal patches can be designed to provide continuous drug delivery as well as improve patient compliance while minimizing systemic adverse effects, they are becoming more widely used than ever before.
Pharmaceutical companies are focusing on the creation of next-generation polymeric transdermal drug delivery systems to keep pace with changing health care needs. The growing demand for transdermal patches that deliver medication in a controlled manner, have extend shelf-life, and stick better to the skin, is projected to increase over time. In addition, the introduction of new materials and technologies will play a key role in differentiating products from competitors and helping to expand the existing market. In addition, new areas of polymer engineering will help drive future innovations in the transdermal drug delivery industry.
The future for polymer-based
transdermal delivery systems of antihypertensives will be greatly influenced by
advancements in technology and the increased focus on individualized medicine. Future
innovations in the pharmaceuticals industry are expected to be based on
patient-centric principles that utilize a multitude of medical-based factors
(i.e. age; skin type; the extent of their disease) to help ensure that each
individual receives the highest possible levels of precision and efficacy when
being treated for their overall health, ultimately leading to improvements in
overall outcomes of all patients treated.
Another important area of research
is the ability of transdermal drug delivery systems to be integrated into
wearable technology. With smart patches embedded with electronic circuitry and
sensors, healthcare practitioners will be able to continuously track a
patient’s physiological parameters while adjusting a drug’s infusion rate in
real-time on an ongoing basis. This type of technology will change the way
hypertension medications are prescribed and managed, by providing a method for
ongoing monitoring and immediate modification of medications used for
hypertension.
Additional studies will look into
how to create a transdermal delivery system that combines multiple
functionalities through the application of polymers, nanotechnology, and
bio-responsive materials. These systems have the potential to increase the
efficiency of drug delivery, improve patient comfort, and eliminate limitations
currently associated with stability and scale of production. Ultimately, the
integration of material science and engineering with digital health technology
will be key in developing successful and durable therapeutic options for
treating hypertension.
6.
CONCLUSION AND RECOMMENDATIONS
Conclusion
This study investigated polymeric
and controlled release mechanisms in designing transdermal antihypertensive
systems to address their growing importance within modern pharmaceutical
sciences. The study indicated that polymer-based systems are key components of
transdermal drug delivery, influencing how quickly drugs are released as well
as their stability, adhesion and, ultimately, therapeutic effect. The ability
to manufacture a diverse range of polymers allowed the design of systems able
to fulfil specific requirements of sustained and controlled release of drug
delivery necessary for successful management of hypertension.
Through this study, the researchers
concluded that controlled release mechanisms provided substantial improvements
in therapeutic effectiveness by providing more stable plasma concentrations of
drug over prolonged periods of time. The three different types of release
mechanisms: diffusion-controlled, swelling-controlled, and erosion-controlled,
provided diverse pathways of controlling the rate of drug release from the
dosage form, allowing for precise modulation of release profiles. These
mechanisms resulted in fewer fluctuations between doses, fewer side effects and
greater patient compliance, which are all considered significant issues
regarding the long-term treatment of hypertension.
Through advancements in polymer
science several types of delivery systems have been created that may help to
improve the stability of medications and how effectively they can be delivered;
for example, smart or stimulus responsive materials, nanocomposite structures,
and biodegradable polymers have all contributed to the development of better
methods for drug delivery including improved interaction with skin barrier
properties; increased percutaneous absorption, and sustained release of drugs. In
addition to improved skin adherence with bioadhesives on transdermal drugs, the
bioadhesives also allow for more reliable and consistent absorption of
medications through the skin. Both improvements mentioned would improve the
overall effectiveness and ease of use of transdermal medication delivery
systems by patients.
Material science and
pharmacokinetics will play a key role in optimizing the performance of
transdermal drug delivery systems. This integration was achieved through the
use of diffusion kinetics and diffusion mechanics for the development of a
sound scientific basis for the efficient design of transdermal drug delivery
systems. By integrating these multidisciplines of science into one body of
study, the pharmacokinetics of how drugs are transported can be understood as a
means to develop consistent and predictable performance characteristics for
transdermal drug delivery systems.
The results clearly indicate that
the advancement of polymer engineering is having a considerable effect on
transdermal antihypertensive therapies. There are still challenges with
stability, cost and scale within transdermal medicated drug delivery, however
continued innovations in the areas of materials science and formulation
technology have enhanced the use of polymer based systems as potential viable
alternatives to traditional means of drug delivery.
Recommendations
From an analysis of findings in this
research, different approaches can be proposed as a means to improve the
development and use of polymeric transdermal systems. First, attention should
be directed at developing non-toxic biodegradable polymeric materials that will
ultimately reduce potential toxicity to patients and the environment as well as
provide patients with a biocompatible product that will support growing trends
toward the use of sustainable pharmaceutical products.
Second, clinical validation over an
extended duration will provide evidence supporting the safety, efficacy and
reliability of advanced polymeric systems. Although promising results have been
reported from laboratory and preclinical studies, valid evidence from clinical
trials is required for acceptance of these systems as being suitable for
general clinical use.
Third, cost-effective manufacturing
methods must be developed because high prices associated with advanced
materials and complicated manufacturing processes impact the ability for these
products to be accessible to patients. Thus, optimising manufacturing methods
to lower cost while preserving quality will be crucial for successful large
scale commercialization for the future.
Finally, there is a need for
regulatory harmonisation, which would facilitate the approval and acceptance of
new polymeric/transdermal systems. By establishing a clear set of guidelines
that could be uniformly applied across several locations, the development of
polymeric transdermal systems can be streamlined and will lead to product
quality and performance consistency across geographic locations.
Future studies should be directed
towards creating new types of Hybrid Systems through computerized designs to
realize the full potential of Polymeric Hybrid Drug Delivery Systems. Research
will now focus on integrating different forms of engineering to create a unique
medicine delivery system that will satisfy today’s obstacles in delivering
medicines. Integrating new materials, and materials that contain or could
potentially contain new properties, could be a big step towards enhancing
patients’ lives.
References
1.
Costa,
P., & Sousa Lobo, J. M. (2001). Modeling and comparison of dissolution
profiles. European Journal of Pharmaceutical Sciences, 13(2), 123–133.
2.
Crank,
J. (1975). The mathematics of diffusion (2nd ed.). Oxford University
Press.
3.
Guy,
R. H. (2010). Transdermal drug delivery. Handbook of Experimental
Pharmacology, 197, 399–410.
4.
Kumar,
R., Philip, A., & Pathak, K. (2016). Nanocomposite materials for drug
delivery. Journal of Drug Delivery Science and Technology, 35, 1–15.
5.
Kwon,
S. S., & Kim, S. Y. (2017). Controlled drug delivery systems for
transdermal applications. Pharmaceutics, 9(3), 35–48.
6.
Langer,
R., & Peppas, N. A. (2003). Advances in biomaterials, drug delivery, and
bionanotechnology. AIChE Journal, 49(12), 2990–3006.
7.
Nair,
L. S., & Laurencin, C. T. (2007). Biodegradable polymers as biomaterials. Progress
in Polymer Science, 32(8–9), 762–798.
8.
Park,
K., Shalaby, W. S. W., & Park, H. (2014). Biodegradable hydrogels for
drug delivery. CRC Press.
9.
Pastore,
M. N., Kalia, Y. N., Horstmann, M., & Roberts, M. S. (2015). Transdermal
patches: History, development and pharmacology. British Journal of
Pharmacology, 172(9), 2179–2209.
10.
Peppas,
N. A., & Sahlin, J. J. (1996). A simple equation for the description of
solute release. International Journal of Pharmaceutics, 57(2), 169–172.
11.
Prausnitz,
M. R., & Langer, R. (2008). Transdermal drug delivery. Nature
Biotechnology, 26(11), 1261–1268.
12.
Siegel,
R. A., & Rathbone, M. J. (2012). Overview of controlled release mechanisms.
In M. J. Rathbone (Ed.), Modified-release drug delivery technology (pp.
19–43). Informa Healthcare.
13.
Siepmann,
J., & Peppas, N. A. (2011). Higuchi equation: Derivation, applications, use
and misuse. International Journal of Pharmaceutics, 418(1), 6–12.
14.
Siepmann,
J., & Siepmann, F. (2012). Modeling of diffusion controlled drug delivery. Journal
of Controlled Release, 161(2), 351–362.
15.
Stuart,
M. A. C., Huck, W. T. S., Genzer, J., Müller, M., Ober, C., Stamm, M.,
Sukhorukov, G. B., Szleifer, I., Tsukruk, V. V., Urban, M., Winnik, F.,
Zauscher, S., Luzinov, I., & Minko, S. (2010). Emerging applications of
stimuli-responsive polymer materials. Nature Materials, 9(2), 101–113.
16.
Whelton,
P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison
Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W.,
MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C.,
Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J.
D., & Wright, J. T. (2018). 2017 guideline for the prevention, detection,
evaluation, and management of high blood pressure in adults. Hypertension,
71(6), e13–e115.